Mycophenolate as induction therapy in lupus nephritis with renal function impairment

American Journal of Nephrology

Volumn 35, Issue 5, 2012, Pages 424-433

  Rivera, F ^a   Fulladosa, X ^b   Poveda, R ^b   Frutos, M A ^c   Garca Fras, P ^c   Ara, J ^d   Illescas, L ^e   Lpez Rubio, E ^e   Mrida, E ^f   Carreo, A ^a   Ballarn, J ^g   Fernndez Jurez, G ^h   Baltar, J ⁱ   Ramos, C ^j   Pons, S ^k   Oliet, A ^k   Vigil, A ^k   Praga, M ^f   Segarra, A ^l  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g FUNDACIÓ PUIGVERT   (Spain)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k HOSPITAL SEVERO OCHOA   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Lupus nephritis; Mycophenolate; Renal failure; Systemic lupus erythematous

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL DISCOMFORT; ACUTE HEPATITIS; ADOLESCENT; ADULT; AGED; CHICKENPOX; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS ABSCESS; PRIORITY JOURNAL; RELAPSE; REVIEW; SEPTICEMIA; SPAIN;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859809585     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000337916     Document Type: Review

References (36)

1. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ: Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3:46-53.
2. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257. (Pubitemid 32799338)
3. Houssiau FA, Vasconcelos C, D'Cruz D, Se-bastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosy ns J P, Cervera R: Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121-2131.
4. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70:732-742. (Pubitemid 44215349)
5. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immu-nopharmacolog y 2000; 47: 85-118. (Pubitemid 30394534)
6. Jones RB, Walsh M, Smith KG: What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis? Curr Opin Rheumatol 2009; 21:256-261.
7. Bomback AS, Appel GB: Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21:2028-2035.
8. Touma Z, Gladman DD, Urowitz MB, Be-yene J, Uleryk EM, Shah PS: Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanaly-sis. J Rheumatol 2011; 38:69-78.
9. Mohan S, Radhakrishnan J: Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75: 233-241.
10. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li L-S, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, the Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclo-phosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
11. Rivera F, Lopez-Gomez JM, Perez-Garcia R: Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66:898-904. (Pubitemid 39120989)
12. Patel SB, Korbet SM, Lewis EJ: The prognosis of severe lupus nephritis based on the modification of diet in renal disease (MDRD) study estimated glomerular filtration rate. Lupus 2011; 20:256-264.
13. Chan TM, Tse KC, Tang CS, Mok MY, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084. (Pubitemid 41710318)
14. El-Shafey EM, Abdou SH, Shareef MM: Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in egyptian patients? Clin Exp Nephrol 2010; 14:214-221.
15. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z: Randomized controlled trial of pulse intravenous cyclo-phosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10:504-510. (Pubitemid 41727277)
16. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cy-clophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228. (Pubitemid 41697285)
17. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L: Induction therapies for class iv lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycopheno-late mofetil or intravenous cyclophospha-mide. Lupus 2007; 16:707-712. (Pubitemid 47517865)
18. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L: Mycophenolate mofetil vs cyclophos-phamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115:705-709. (Pubitemid 34594285)
19. Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D: Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 10 0:c92-c10 0. (Pubitemid 40868991)
20. Elyan M, Ballou S: The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin R heumatol 2009; 28: 835-840.
21. Kasitanon N, Petri M, Haas M, Magder LS, Fine DM: Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent prolif-erative disease: a retrospective study of 29 cases. Lupus 2008; 17:40-45. (Pubitemid 351487018)
22. Kitiyakara C, Ophascharoensuk V, Chang-sirikulchai S, Ingsathit A, Tankee P, Sang-panich A, Sumethkul V: Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol 2008; 69:90-101. (Pubitemid 351227961)
23. Lu F, Tu Y, Peng X, Wang L, Wang H, Sun Z, Zheng H, Hu Z: A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008; 17: 622-629.
24. Weng MY, Weng CT, Liu MF: The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 2010; 29:771-775.
25. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49:128-140.
26. Frutos MA, Martín A, de Ramon E, Camps MT, Valera A, García I, Fernández-Nebro A: Ciclofosfamida intravenosa en el tratamien-to de la nefritis lúpica: veinte años reducien-do dosis. Nefrologia 2007; 27:12-22.
27. Gil CM, Rivera F, Crespo A, Egea JJ, Gil MT, Olivares J: Evolución de la nefropatía lúpica grave tratada con ciclofosfamida parenteral y esteroides orales. Nefrologia 1999; 19: 514-521.
28. Sisó A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Nardi N, Testi A, Perez-de-Lis M, Diaz-Laga res C, Darnel l A, Sentis J, Coca A: Outcomes in biopsy-proven lupus nephritis: Evaluation of 190 white patients from a single center. Medicine (Baltimore) 2010; 89: 300-307.
29. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR: Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analy-sis. Clin J Am Soc Nephrol 2007; 2:968-975.
30. Tang Z, Yang G, Yu C, Yu Y, Wang J, Hu W, Z eng C, Chen H, Liu Z, Li L: Effects of myco-phenolate mofetil for patients with crescen-tic lupus nephritis. Nephrology (Carlton) 2008; 13: 702-707.
31. Walsh M, Solomons N, Jayne D, Aspreva Lupus Management Study Groups: Mycophe-nolate mofetil in patients with lupus nephritis and poor renal function: Results from a randomised control trial. J Am Soc Nephrol 2008; 19:abstr sa-po2953.
32. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB: My-cophenolate mofetil and intravenous cyclo-phosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152-160.
33. Lertdumrongluk P, Somparn P, Kittana-mongkolchai W, Traitanon O, Vadchara-vivad S, Avihingsanon Y: Pharmacokinetics of mycophenolic acid in severe lupus nephritis. K idney Int 2010; 78: 389-395.
34. Kamanamool N, McEvoy M, Attia J, Ingsa-thit A, Ngamjanyaporn P, Thakkinstian A: Efficacy and adverse events of mycopheno-late mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010; 89:227-235.
35. Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D'Cruz DP, Abbs IC, Khamasta MA, Hughes GR: Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tol-erability in 86 patients. J Rheumatol 2005; 32: 1047-1052. (Pubitemid 40828077)
36. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG: Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010; 19: 703-710.